3-(1-pyridin-3-yl-ethoxy)-5-(3-pyridin-2-ylmethyl-ureido)-isothiazole-4-carboxylic acid amide | 727359-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(1-pyridin-3-yl-ethoxy)-5-(3-pyridin-2-ylmethyl-ureido)-isothiazole-4-carboxylic acid amide
• 英文别名: 3-(1-Pyridin-3-ylethoxy)-5-(pyridin-2-ylmethylcarbamoylamino)-1,2-thiazole-4-carboxamide
• CAS: 727359-75-3
• 化学式: C₁₈H₁₈N₆O₃S
• 分子量: 398.445
• InChiKey: KXKBJYYZISXQNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  160
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Isothiazole derivatives
  申请人：Pfizer Inc

  公开号：US20040147574A1

  公开（公告）日：2004-07-29

  Novel isothiazole compounds, including derivatives thereof, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, hyperproliferative disorders and fibrotic diseases.

  本发明描述了新型异噻唑化合物（包括其衍生物）、含有它们的药物组合物以及它们的医疗用途。本发明的化合物是转化生长因子（"TGF"）-&bgr 信号通路的强效抑制剂。它们可用于治疗各种与 TGF 相关的疾病，例如过度增殖性疾病和纤维化疾病。
• ISOTHIAZOLE DERIVATIVES
  申请人：Pfizer Products Inc.

  公开号：EP1590347A1

  公开（公告）日：2005-11-02
• EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS
  申请人：Ichida Justin

  公开号：US20120021519A1

  公开（公告）日：2012-01-26

  The disclosure features a method of producing a reprogrammed cell (e.g. an induced pluripotent stem cell or an undifferentiated cell) from a differentiated (e.g. somatic) cell. In some embodiments, the methods includes contacting a differentiated (e.g. somatic cell) with a TGFBR1 inhibitor or anti-TGF-β-antibody to produce a reprogrammed cell (e.g. pluripotent stem cell or undifferentiated cell). Embodiments of the present invention relate to a reprogrammed cell and methods and compositions for producing a chemically produced reprogrammed cell or populations thereof.
• TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20140120621A1

  公开（公告）日：2014-05-01

  In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGFβR) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGFβR inhibitor. Further described herein are kits for producing iPS cells using a TGFβR inhibitor.
• US8298825B1
  申请人：——

  公开号：US8298825B1

  公开（公告）日：2012-10-30